Treatment in Autoimmune Disease
Anokion is an innovative immune tolerance company focused on providing a more effective approach to treating autoimmune disease. Our proprietary immune tolerance platform features proteins, or antigens, that are engineered to deliver precise, targeted disease therapy, without the side effects of broad immunosuppression. Anokion’s antigen-specific platform can be translated to virtually any antigen-mediated disease, with widespread potential across multiple clinical applications.
- October 12, 2023
Anokion Announces Upcoming Oral Presentation of Phase 1 Clinical Data with KAN-101 for Celiac Disease During United European Gastroenterology Week| Read More